Korean Medical Startup Cellbion Raises KRW 8 billion for Innovative Cancer Radiotherapy Drug
Reading Time: < 1 minuteKorean medical radioisotope-based cancer therapeutics developer, Cellbion, has raised KRW 8 billion in a pre-IPO round, featuring investors like Hana Ventures, Huons, and Sinsin Pharm. Cellbion plans to leverage this investment for its listing on the KOSDAQ market in the second half of the next year.
The company’s pipeline includes Lu-177-DGUL, an innovative treatment for end-stage prostate cancer patients who have failed standard therapies. This radiotherapy drug works by delivering radiation to prostate cancer cells, inducing DNA damage and cell death.
It’s the result of a collaboration between Cellbion and Seoul National University Hospital, highlighting the nation’s R&D capabilities. Lu-177-DGUL is currently in phase 2 clinical trials in Korea, showing promising results with a significant reduction in PSA levels and tumor size in patients.
The drug’s exceptional clinical results have attracted attention from both domestic and global pharmaceutical companies, with Cellbion engaging in discussions with prominent names like Novartis, Lilly, BMS, and AstraZeneca.
Hana Ventures cited the rapidly growing radioisotope pharmaceutical market and Cellbion’s strong clinical data as reasons for their investment.
Cellbion plans to expand clinical trial sites after completing phase 2, aiming for a market launch post-trials.
[Korean bioHealth Startups News]
- MedInTech Secures 20 billion KRW Series B Investment for Innovative Medical Endoscope
- Korea’s MSS Hosts Korea-Japan Bio Ecosystem Roundtable: Fostering Collaboration Between Both Nations
- ‘RADICURE’ Secures pre-Series A funding for Innovative Digital X-ray Dementia Treatment
- Dreampac Secures Funding to Develop PIPAC for Treating Peritoneal Carcinomatosis
- Rexpharm Forms MOU with Timely Basket to Develop and Distribute Health Foods in U.S.
- SEOUL BIOHUB Global Center Opens, Aiming to Boost Global BioTech Competitiveness
- Delight Room Invests in Soundable Health for Advanced Sound Analysis in Healthcare
- Apollon Secures 2.3 Billion KRW in Funding for Innovative Needle-Free CGM Technology
- Korean Space Medicine Startup SpaceLiintech Lands 4 Billion KRW Series A Funding
- ArtBlood Secures KRW 6.5 Billion in Series A for Synthetic Blood Production